180 related articles for article (PubMed ID: 32421817)
21. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.
Wada N; Yoshida A; Miyagi Y; Yamamoto T; Nakayama H; Suganuma N; Matsuzu K; Masudo K; Hirakawa S; Rino Y; Masuda M; Imada T
Anticancer Res; 2008; 28(1A):139-44. PubMed ID: 18383837
[TBL] [Abstract][Full Text] [Related]
23. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization.
Miura D; Wada N; Chin K; Magrane GG; Wong M; Duh QY; Clark OH
Thyroid; 2003 Mar; 13(3):283-90. PubMed ID: 12729478
[TBL] [Abstract][Full Text] [Related]
25. Significance of oncocytic features in poorly differentiated thyroid carcinoma - a bi-institutional experience.
Xu B; Lubin DJ; Dogan S; Ghossein RA; Viswanathan K
Virchows Arch; 2023 Mar; 482(3):479-491. PubMed ID: 36346459
[TBL] [Abstract][Full Text] [Related]
26. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
[TBL] [Abstract][Full Text] [Related]
27. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
Ibrahimpasic T; Ghossein R; Shah JP; Ganly I
Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050
[TBL] [Abstract][Full Text] [Related]
28. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R
Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
30. Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer.
Murugan AK; Qasem E; Al-Hindi H; Shi Y; Alzahrani AS
J Transl Med; 2016 Jul; 14(1):204. PubMed ID: 27387551
[TBL] [Abstract][Full Text] [Related]
31. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
[TBL] [Abstract][Full Text] [Related]
32. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.
van der Tuin K; Ventayol Garcia M; Corver WE; Khalifa MN; Ruano Neto D; Corssmit EPM; Hes FJ; Links TP; Smit JWA; Plantinga TS; Kapiteijn E; van Wezel T; Morreau H
Eur J Endocrinol; 2019 Apr; 180(4):235-241. PubMed ID: 30668525
[TBL] [Abstract][Full Text] [Related]
33. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
34. FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.
Tsuchida N; Ikeda MA; Ιshino Υ; Grieco M; Vecchio G
Int J Oncol; 2017 Jun; 50(6):2043-2048. PubMed ID: 28440416
[TBL] [Abstract][Full Text] [Related]
35. Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel.
Alzahrani AS; Alswailem M; Alswailem AA; Al-Hindi H; Goljan E; Alsudairy N; Abouelhoda M
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32556222
[TBL] [Abstract][Full Text] [Related]
36. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
[TBL] [Abstract][Full Text] [Related]
37. Primary Versus Secondary Anaplastic Thyroid Carcinoma: Perspectives from Multi-institutional and Population-Level Data.
Ngo TNM; Le TTB; Le T; Bychkov A; Oishi N; Jung CK; Hassell L; Kakudo K; Vuong HG
Endocr Pathol; 2021 Dec; 32(4):489-500. PubMed ID: 34559383
[TBL] [Abstract][Full Text] [Related]
38. The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer.
Mika J; Łabaj W; Chekan M; Abramowicz A; Pietrowska M; Polański A; Widłak P
J Appl Genet; 2021 Feb; 62(1):115-120. PubMed ID: 33222100
[TBL] [Abstract][Full Text] [Related]
39. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
40. Predictors of thyroid tumor aggressiveness.
Clark OH
West J Med; 1996 Sep; 165(3):131-8. PubMed ID: 8909165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
